NBI-31772 hydrate 是胰岛素样生长因子IGF与IGFBP相互作用的有效抑制剂。NBI-31772 hydrate 也是一种非肽类配体，可从其结合蛋白复合物 IGF-I/IGFBP-3 中释放生物活性 IGF-I (对六种人类亚型的Ki=1-24 nM) 。具有抗焦虑和抗抑郁作用。

NBI-31772 hydrate is a potent inhibitor of interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs). NBI-31772 hydrate is also a nonpeptide ligand that releases bioactive IGF-I from the IGF-I/IGFBP-3 complex ( K i s=1-24 nM for all six human subtypes). Anxiolytic and antidepressant-like effects [1] [2] [3].

NBI-31772 (5-100 μg; icv; immediately or at 1, 2, or, 3 hours after MCAO) at the time of ischemia onset also dose-dependently reduced infarct size, and the highest dose (100 μg) significantly reduced both total and cortical infarct volume [3]. Animal Model: Sprague-Dawley rats (subtemporal middle cerebral artery occlusion model, MCAO) [3] Dosage: 5-100 μg Administration: Icv; immediately or at 1, 2, or, 3 hours after MCAO Result: Resulted in a significant reduction of the total and cortical lesion volume.

C17H13NO8

372.82

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years